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ABSTRACT Innate immune functions are known to
be compromised during sepsis, often with lethal conse-
quences. There is also evidence in rats that sepsis is
associated with excessive complement activation and
generation of the potent anaphylatoxin C5a. In the
presence of a cyclic peptide antagonist (C5aRa) to the
C5a receptor (C5aR), the binding of murine 125I-C5a to
murine neutrophils was reduced, the in vitro chemotac-
tic responses of mouse neutrophils to mouse C5a were
markedly diminished, the acquired defect in hydrogen
peroxide (H2O2) production of C5a-exposed neutro-
phils was reversed, and the lung permeability index
(extravascular leakage of albumin) in mice after in-
trapulmonary deposition of IgG immune complexes
was markedly diminished. Mice that developed sepsis
after cecal ligation/puncture (CLP) and were treated
with C5aRa had greatly improved survival rates. These
data suggest that C5aRa interferes with neutrophil
responses to C5a, preventing C5a-induced compromise
of innate immunity during sepsis, with greatly improved
survival rates after CLP.—Huber-Lang, M. S., Riede-
man, N. C., Sarma, J. V., Younkin, E. M., McGuire,
S. R., Laudes, I. J., Lu, K. T., Guo, R.-F., Neff, T. A.,
Padgaonkar, V. A., Lambris, J. D., Spruce, L., Mastellos,
D., Zetoune, F. S., Ward, P. A. Protection of innate
immunity by C5aR antagonist in septic mice. FASEB J.
16, 1567–1574 (2002)
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The systemic inflammatory response during sepsis is
characterized by an excessive stimulation of inflamma-
tory pathways (1) and impairment of innate immunity
(2). Whereas the complement cascade (3–5) and the
chemokine-cytokine networks (6, 7) are strongly acti-
vated during sepsis, innate immune function is severely
compromised, as reflected by impairment of phagocytic
cell function (phagocytosis, chemotaxis, and H2O2
production) during sepsis (2, 8–10). In humans with
sepsis, harmful outcomes have been correlated with
increased plasma levels of complement activation prod-
ucts C3a, C4a, and C5a (9, 11) together with impair-
ment of the bactericidal activity of neutrophils (8, 12,
13). The complement activation product C5a and re-
ceptor interactions with complement activation prod-
ucts (14) have been shown to play a pivotal role in
development of the systemic inflammatory response
during experimental sepsis (3) and in sepsis-induced
multiorgan failure (MOF) (4, 15). After intraperitoneal
(i.p.) injection of zymosan particles, which induce
potent complement activation and MOF, C5-deficient
(C5/) mice exhibited increased survival rates (15).
In a model of acute endotoxemia, C5/ mice showed
improved hepatic and pulmonary function compared
with their C5/ littermates (16). In rats undergoing
the cecal ligation/puncture (CLP), which closely mim-
ics the pathophysiology of human sepsis (17, 18), we
have recently shown that intravenous (i.v.) administration
of antibodies to C5a has substantial protective effects.
These were associated with preservation in blood neutro-
phils of C5a binding sites and retention of the oxidative
burst, concomitant reduction in levels of bacteremia, and
improved multi-organ function (3, 4, 19).
The various effects of C5a have been the subject of
many studies, particularly its interaction with the C5a
receptor (C5aR), which is expressed on numerous my-
eloid (20–22) and nonmyeloid cells (23–25). In C5aR-
deficient mice (C5aR/), IgG immune complex (IC)
-induced inflammatory responses in lungs, peritoneum,
and skin were attenuated, associated with reduced neu-
trophil influx and reduced microvascular permeability
changes (26), implying an important role for C5aR in the
mechanisms of these inflammatory responses. In sepsis,
blockade of C5aR by C5aRa was considered to be an
intervention that might protect against excessive C5a
production and related impairment of innate immunity.
Using C5aRa, F[OPdChaWR] (Phe-[Orn-Pro-D-cyclo-
hexylalanine-Trp-Arg]) (27, 28), we demonstrate that this
inhibitor blocks binding of C5a to mouse neutrophils and
the ability of these cells to respond chemotactically to
recombinant mouse C5a. We show the ability of C5aRa to
prevent loss of the respiratory burst in mouse neutrophils
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exposed to C5a. We also demonstrate the ability of C5aRa
to reduce lung injury after IC deposition and to dramat-
ically improve survival rates in CLP mice.
MATERIALS AND METHODS
Reagents and chemicals
All materials were obtained from Sigma Chemical Co. (St.
Louis, MO) unless otherwise indicated.
Cloning and expression of mC5a
Total RNA was isolated from normal mouse liver tissue using the
guanidine isothiocyanate method. The mC5a sequence was
subcloned into pET 15b expression vector (Novagen, Madison,
WI) using the primers 5-GTG TCG CGA GTC AGC CAT ATG
AAC CTG CAT CTC CTA-3 (sense, NdeI site underlined) and
5-GTC ACA TCG CGA CAC GGA TCC TCA CCT TCC CAG
TTG GAC-3 (antisense, BamHI site underlined). After expres-
sion of mouse C5a in BL21 (DE3) pLysS cells (Novagen,
Madison, WI), the recombinant protein was purified over a Ni2
column and used for subsequent experiments. As will be shown
later, mC5a had biological (chemotactic) activity and demon-
strated high-affinity binding to mouse neutrophils.
Synthesis and purification of C5aRa F[OPdChaWR]
Synthesis of the linear hexapeptide F[OPdChaWR] was done
as described previously (29), followed by cyclization involving
the side chain of ornithine and carboxyl-terminal arginine
(27). The peptide was purified using preparative reversed-
phase HPLC. Eluted fractions were characterized by mass
spectrometry (matrix-assisted laser desorption ionization).
The efficacy of the cyclic hexapeptide F[OPdChaWR] was
characterized in vivo and in vitro, as described below.
Models of inflammation
Cecal ligation puncture-induced sepsis
Male specific pathogen-free B10.D2/nSnJ mice (6 to 8 wk of
age weighing 25–30 g; Jackson Laboratories, Bar Harbor, ME)
were used in all experiments. Mice were anesthetized with
ketamine i.p. (20 mg/100 g body weight). A 1 cm-long
midline incision was made to expose the cecum and adjoin-
ing intestine. With a 4–0 silk suture, the cecum was tightly
ligated below the ileocecal valve without causing bowel ob-
struction. The cecum was punctured through and through
with a 21 gauge needle and gently squeezed to extrude
luminal contents, ensuring patency of the two puncture
holes. The abdominal incision was then closed with a 4–0
nylon suture and skin metallic clips (Ethicon, Somerville,
NY). Sham-operated animals underwent the same procedure
except for ligation and puncture of the cecum. Immediately
thereafter, CLP mice received either 200 L of saline alone or
C5aRa in 200 L saline i.v. (at a final concentration of 1–3
mg/kg body weight). In one experiment, i.v. infusion of
C5aRa was delayed for 6 h. Before and after surgery, mice had
unrestricted access to food and water. Survival rates were
determined over a 9 day period, with assessment every 6 h.
IgG immune complex-induced lung injury
Male specific pathogen-free B10.D2/nSnJ mice were anesthe-
tized i.p. with ketamine (20 mg/100 g body weight). To
induce acute inflammatory lung injury, mice were intratra-
cheally instilled with 250 g antibody to bovine serum albu-
min (anti-BSA; ICN Biomedicals, Costa Mesa, CA) in a
volume of 40 L DPBS (Gibco BRL, Grand Island, NY),
followed by i.v. injection of 500 g BSA (1 ng endotoxin/
mg) in 200 L DPBS. Some animals received C5aRa (1
mg/kg body weight) intratracheally together with the anti-
BSA. Negative control animals were subjected to intratracheal
instillation of 40 L DPBS alone. For analysis of pulmonary
vascular permeability, trace amounts of 125I-labeled BSA were
injected i.v. Four h after IgG immune complex deposition,
mice were killed, the pulmonary circulation flushed with 1
mL DPBS by pulmonary artery injection, and the lungs
surgically removed. The extent of lung injury was quantified
by calculating the lung permeability index, determined by
comparing the amount of 125I-BSA present in lung paren-
chyma to the amount present in 100 L blood obtained from
the inferior vena cava at the time of death.
Isolation of mouse peritoneal neutrophils
Mice were injected i.p. with 2.5 mL sterile 3% thioglycolate
medium (DIFCO Laboratories, Detroit, MI) for harvesting of
mouse neutrophils (30). Five hours later, mice were killed
and the peritoneal cavity was lavaged four times with 10 mL
DPBS. Fluids were centrifuged and residual red blood cells
removed by a hypotonic lysis step. Remaining peritoneal cells
were washed and resuspended in HBSS. Aliquots of cells were
stained with Diff-Quik Stain (Dade International, Miami, FL)
and examined for neutrophil purity (95%) and viability
(97%) by trypan blue exclusion (31).
Radiolabeling and binding assays
For binding studies, mC5a was labeled with 125I using the
chloramine T-based protocol (32) with gentle oxidation,
which preserves chemotactic activity of mC5a for mouse
neutrophils (data not shown). Isolated neutrophils were
incubated for 1 h at 4°C in binding buffer (HBSS without
Ca2 and containing 1% BSA) to block nonspecific surface
binding sites. After gentle washing, neutrophils (2106 cells)
were incubated at 4°C in binding buffer (HBSS with Ca2
containing 0.1% BSA) (in a final volume of 200 L) with 100
pM 125I-mC5a (specific activity 23.5 Ci/g) in the absence
or presence of increasing amounts of either unlabeled mC5a
or C5aRa (ranging from 1012 to 104 M). After an incuba-
tion interval of 20 min at 4°C, cell suspensions were layered
over 20% sucrose and sedimented by centrifugation at 11,000
g (Beckman Microfuge B, Palo Alto, CA) for 2 min. The tubes
were then frozen at 80°C and the tips containing the cell
pellet were cut off to determine the cell-bound 125I-mC5a,
using a gamma counter (1261 Multigamma, EG & G Wallac,
Co., Gaithersburg, MD). Binding affinities (Kd values) of C5a
were calculated in the conventional manner (22).
In another set of experiments, C5aRa was labeled with 125I
by the chloramine T method, taking advantage of the elec-
trophilic aromatic region of phenylalanine (33). The integrity
of 125I-C5aRa after the labeling procedure was confirmed in
vitro by chemotaxis assays (see below). Using peritoneal
mouse neutrophils, competitive binding studies using 100 pM
125I-C5aRa (specific activity 33.9 Ci/g) with increasing
amounts of unlabeled C5aRa or mC5a were performed as
described above.
Chemotaxis assay
After neutrophil isolation, cells were fluorescein-labeled with
BCECF (2,7-bis [2-carboxyethyl]-5-[and 6]-carboxy-fluores-
cein acetoxymethyl ester) (Molecular Probes, Eugene, OR).
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Labeled neutrophils (5106 cells/mL) were then loaded into
the upper chambers of 96-well minichambers (NeuroProbe,
Cabin John, MD). Lower chambers were loaded with increas-
ing amounts of mC5a in the presence or absence of different
concentrations of C5aRa, ranging from 0.1 nM–10 M. The
upper and lower chambers were separated by a polycarbonate
membrane of 3 m porosity. Minichambers were incubated
for 60 min at 37°C. The number of cells migrating through
polycarbonate filters to the lower surface was measured by
cytofluorometry (Cytofluor II, PerSeptive Biosystems, Fra-
mingham, MA). For each measurement, quadruplicate sam-
ples were used.
Measurement of neutrophil oxidative burst
H2O2 generation was determined in the presence of 1 mM
sodium azide. As indicated, mouse neutrophils (2106 cells/
mL) were pretreated with mC5a (10 nM) for 60 min at 37°C
in the presence or absence of different amounts of C5aRa. To
stimulate neutrophils, cells were then incubated with PMA
(25 ng/mL) for an additional 10 min. The reaction was
stopped by addition of 0.1 mL trichloroacetic acid (50% v/v),
then ferrous ammonium sulfate (1.5 mM) and potassium
thiocyanate (0.25 M) were added to supernatant fluids. The
absorbance of the ferrithiocyanate complex was measured at
480 nm and compared with a standard curve generated from
dilutions of reference solutions of H2O2.
Clearance studies
To evaluate the blood clearance of C5aRa, anesthetized mice
were injected i.v. with C5aRa (1 mg/kg body weight) in 200
L DPBS containing trace amounts of 125I-C5aRa (specific
activity 33.9 Ci/g). Sixty seconds after administration, 5 L
blood was drawn from a small incision at the tail tip, followed
by direct pressure to stop further bleeding. Animals were
killed after specified periods (1, 2, 3, 6, 12, 24, 36, 48, 72,
96 h) and the radioactivity of blood samples (100 L aliquots)
was measured in a gamma counter (1261 Multigamma,
EG&G, Wallac, Gaithersburg, MD) and compared with the
value obtained 1.0 min after infusion of C5aRa.
Statistical analyses
All values were expressed as mean  se. Results were consid-
ered statistically significant where P  0.05. For analysis of
survival curves, log rank and 2 log rank tests were used.
Outcomes in different treatment groups were compared
using 	2 and Fisher’s exact tests. Data sets of binding,
chemotaxis and oxidative burst assays were analyzed with
one-way ANOVA; differences in the mean values among
experimental groups were then compared using the Tukey
multiple comparison test.
RESULTS
Ability of C5aRa to reduce binding of mC5a
to mouse peritoneal neutrophils
Recent reports have described C5aRa binding affinities
to rat and human neutrophils (28, 34). To assess
whether C5aRa also binds to mouse neutrophils, com-
petitive binding studies using C5aRa and mC5a were
undertaken. Mouse neutrophils (isolated from perito-
neal exudates) were incubated for 20 min at 4°C with
100 pM 125I-mC5a in the presence of increasing doses
of either unlabeled mC5a or C5aRa. As shown in Fig. 1
(filled circles), mC5a demonstrated dose-dependent
competitive binding, with a calculated Kd of 
3 nM.
C5aRa (open circles) also demonstrated significant
competitive binding with a calculated Kd of 
30 nM.
These experiments indicate that C5aRa inhibits the
binding of mC5a to mouse neutrophils.
Blocking by C5aRa of mouse neutrophil chemotactic
responses to mC5a
To assess in vitro the effects of C5aRa on migrational
responses of mouse neutrophils to mC5a, chemotactic
responses in the absence or presence of a dose range of
C5aRa were determined. When mouse neutrophils
were exposed to mC5a (0.01–1000 nM), a typical dose-
dependent chemotactic response was found, reaching a
plateau between 1 and 10 nM mC5a (Fig. 2A, filled
circles). In the presence of 1000 nM C5aRa, the che-
motactic response of mouse neutrophils was almost
completely suppressed over a wide dose range (0.01–
100 nM) of mC5a.
In a second set of experiments, the chemotactic
responses of mouse neutrophils to a constant dose (10
nM) of mC5a in the presence of increasing C5aRa
concentrations (0.1 nM–10 M) were assessed (Fig.
2B). The presence of 10 nM C5aRa alone evoked a very
weak chemotactic response, if at all (gray bar). As
expected, 10 nM mC5a in the absence of C5aRa evoked
a robust chemotactic response of neutrophils (first
black bar). In contrast, a dose-dependent inhibition of
neutrophil response to mC5a was observed in the
copresence of 0.1–104 nM C5aRa. In this assay the
calculated IC50 for C5aRa was 
0.5 nM. These data
indicate a dose-dependent inhibition by C5aRa of che-
motactic responses by mouse neutrophils to mC5a.
Figure 1. Inhibition of 125I-recombinant mouse (m) C5a
binding to mouse neutrophils in the presence of increasing
concentrations of unlabeled mC5a or C5aRa. Data are ex-
pressed as a percent of binding values using 100 pM 125I-
mC5a.
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Reversal by C5aRa of C5a-induced defect in the
oxidative burst of neutrophils
During sepsis, plasma levels of C5a are increased (9, 11)
and suppression of the neutrophil oxidative burst (pro-
duction of O2F and H2O2) occurs, resulting in im-
paired bacterial killing (3, 13). In CLP-induced sepsis
in rats, we have recently shown that the H2O2 response
of blood neutrophils is defective (3). In vitro exposure
of neutrophils to C5a reproduces the defect in the
oxidative response found in blood neutrophils during
sepsis (3). In the current study, we evaluated the effects
of C5aRa on the C5a-induced loss of the oxidative
response in neutrophils. Mouse neutrophils were ex-
posed to buffer (ctrl), to 10 nM mC5a alone, or to 10
nM C5aRa alone for 60 min at 37°C, followed by
addition (where indicated) of PMA (25 ng/mL for 10
min at 37°C). The H2O2 response was then measured.
As shown in Fig. 3, neither mC5a alone nor C5aRa
alone significantly altered basal H2O2 production in
neutrophils when compared with ctrl cells (white bar
and first two light gray bars). Addition of PMA to
neutrophils otherwise untreated caused the expected
robust increase in H2O2 generation (black bar). In
mC5a-exposed neutrophils (in the absence of C5aRa),
followed by stimulation with PMA, production of H2O2
was completely abolished (first cross-hatched bar). The
copresence of 10 nM mC5a with increasing concentra-
tions of C5aRa (10 nM–10 M) with neutrophils for 60
min at 37°C led to a progressive and significant resto-
ration of H2O2 generation (second to fifth cross-
hatched bars). Thus, C5a-induced impairment of the
oxidative response in activated neutrophils could be
reversed by the presence of C5aRa in a dose-dependent
manner. These data parallel the efficacy of C5aRa in
blockade of C5a-dependent neutrophil chemotactic
activity (Fig. 2B).
C5aRa clearance in mouse blood
To determine whether treatment of CLP mice with
C5aRa would improve survival rates, we first assessed
the in vivo blood clearance of C5aRa. C5aRa was
125I-labeled before i.v. administration into mice. To
ensure the functional integrity of C5aRa after the
labeling procedure, chemotaxis assays were performed
using 125I-C5aRa (10 nM) in the presence of mC5a
(1–100 nM). Mouse neutrophils were exposed to a
range of concentrations of mC5a in the absence or
presence of 10 nM 125I-C5aRa, similar to the protocol in
Fig. 2B. As shown in Fig. 4 (inset), radiolabeled C5aRa
virtually completely suppressed the chemotactic re-
sponse to all doses of mC5a (open circles), indicating
intact biological activity of 125I-C5aRa. The blood clear-
ance of C5aRa in mice after a single i.v. bolus of 1
mg/kg C5aRa with trace amounts of 125I-labeled C5aRa
was determined. As shown in Fig. 4, a multiphasic
decline in whole blood concentrations was observed.
The early, rapid clearance phase (3 h) was character-
ized by a mean half-life of
4 h, whereas the later phase
(24–72 h) demonstrated a mean half-life of
12 h. The
slower clearance phase accounted for an average of
63% of the total area for the blood concentration vs.
Figure 3. In vitro effects of C5aRa on reversal of C5a-induced
defective H2O2 responses of mouse neutrophils stimulated
with PMA (25 ng/mL). Neutrophils were preincubated with
10 nM mC5a for 1 h at 37°C in the presence or absence of
C5aRa, then stimulated with PMA.
Figure 2. Inhibitory effects of C5aRa on chemotactic re-
sponses of mouse neutrophils to recombinant mouse C5a. A)
Chemotactic responses of mouse neutrophils to a range of
concentrations of recombinant mouse C5a in the absence
(filled circles) or presence of 1.0 M C5aRa (open circles). B)
Blockade of chemotactic activity (using 10 nM mC5a) of
mouse neutrophils in the presence of a range of concentra-
tions of C5aRa.
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time; 36 h after C5aRa application, the C5aRa concen-
tration reached 10% of the initial dose in blood.
Ability of C5aRa to diminish C5a-dependent
inflammatory lung injury in mice
Lung inflammatory injury induced by intrapulmonary
deposition of IgG immune complex is C5 and C5a
dependent (35, 36). In the case of C5a, the bulk of C5a
generated appears to be within the distal airway com-
partment (36). In preliminary experiments, we deter-
mined that the intratracheal instillation of 250 g
anti-BSA with an i.v. infusion of 500 g BSA would
induce acute inflammatory injury in mouse lung at 4 h
(data not shown). Accordingly, these conditions were
used in the mouse model of acute lung injury. To
determine lung vascular leakage 4 h after immune
complex deposition, extravasation of i.v. administered
125I-labeled BSA into lungs was measured. Control
(ctrl) mice, which received 40 L sterile saline intratra-
cheally, exhibited a vascular permeability index of
0.13  0.02 (Fig. 5). This index rose nearly ninefold
in mice with immune complex-induced alveolitis.
However, the presence of C5aRa (1 mg/kg body
weight given intratracheally at time 0) resulted in a
substantial reduction in the permeability index (im-
mune complexC5aRa) vs. the positive control group
of immune complexes alone. The C5aRa-treated group
showed a significant reduction (
70%, P0.05) in the
permeability index. Higher doses of C5aRa (up to 10
mg/kg) did not further reduce the permeability index
(data not shown). Thus, in animals receiving a direct
intrapulmonary insult after deposition of IgG immune
complexes, airway presence of C5aRa caused signifi-
cantly reduced lung vascular leakage.
Protective effects of C5aRa in CLP-induced sepsis
Mice with CLP-induced sepsis received i.v. either 200
L sterile saline immediately after the CLP procedure
or C5aRa (1.0–3.0 mg/kg body weight) in 200 L
sterile saline. Survival of mice was assessed over a 9 day
period. In one group, the infusion of C5aRa was
delayed until 6 h after CLP. The data are shown in Fig.
6. In the sham-operated group, which underwent the
same surgical procedure without CLP, all animals sur-
vived the 9 day interval (n10) (data not shown). Mice
subjected to CLP in the absence of a protective inter-
vention (saline) developed typical clinical signs of
sepsis 12–24 h after CLP: decreased physical activity,
lethargy, loss of congregation for group warmth, dehy-
Figure 4. Blood clearance of 125I-C5aRa in mice. After 125I-
labeling of C5aRa, its functional activity was determined in
chemotaxis assays using increasing amounts of mC5a in the
presence of 10 nM 125I-C5aRa (inset). Semilogarithmic plots
of blood clearance curve of 125I-C5aRa were normalized to
the 1.0 min time point. Data are expressed as percent of
blood values obtained immediately after i.v. injection of
125I-C5aRa. Mean  se of 5 animals at each time point.
Figure 5. Effects of C5aRa (1 mg/kg body weight adminis-
tered intratracheally) on acute inflammatory injury of mouse
lungs after intrapulmonary deposition of IgG immune com-
plexes. The lung vascular permeability index was assessed by
measuring extravasation of i.v. administered 125I-BSA 4 h after
initiation of the reactions. Negative control group (ctrl);
intrapulmonary deposition of IgG immune complexes (IC) in
the absence or presence of 1 mg/kg body weight C5aRa
(ICC5aRa). For each group, n  6.
Figure 6. Survival curves of mice after CLP as a function of i.v.
treatment with either 200 L saline alone or C5aRa (1–3
mg/kg body weight) in 200 L saline. Also indicated is a
group treated with C5aRa (3 mg/kg body weight) 6 h after
CLP. For each group, n  10.
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dration, piloerection, glazed eyes with crusting exu-
dates, diarrhea, and dark urine. The survival rate by the
third day in this group was only 10% but 60% in the
C5aRa-treated group (1 mg/kg at time 0) survived. By
day 7 there were no survivors in the CLP group not
receiving protective intervention, whereas in the
C5aRa-treated group (1–3 mg C5aRa/kg at time 0) at
day 4 and beyond survival remained constant at 60%.
By the fifth day in the CLP group treated with C5aRa,
there were no clinical signs of sepsis. Differences be-
tween the 9 day outcomes of CLP animals that did not
receive C5aRa and those that received C5aRa (1 or 3
mg/kg) were statistically significant (P0.03 for the
C5aRa-treated CLP group vs. CLP unprotected group
and P0.05 for the C5aRa-treated CLP groups vs. sham
operated group, respectively), indicating significantly
improved survival rates by administration of C5aRa.
The survival pattern in CLP mice receiving 3.0 mg/kg
body weight was the same as those receiving 1.0 mg
C5aRa/kg body weight. When C5aRa (3 mg/kg body
weight) was given 6 h after CLP, the protective effects
were lost (Fig. 6), suggesting that interception of C5a
by C5aRa in this model must occur in the first few hours
of sepsis for clinical benefit.
DISCUSSION
The innate immune response provides the body with
host defenses that represent the first line of protection
against bacterial infections (37). During the systemic
inflammatory response in sepsis, the protective func-
tions of neutrophils are significantly compromised,
seriously impairing the clearance of bacteria from
blood (3, 13), with resultant organ damage (2, 4, 9) and
a high incidence of lethality (2, 11). In experimental
sepsis induced by CLP, C3/ or C4/ mice were
more sensitive to the lethal effects of CLP compared
with wild-type controls, suggesting that complement is
essential for the full expression of innate immunity
during polymicrobial sepsis (38). Recent studies with
complement receptor 2-deficient (CR2/) (39) or
C3aR/ mice (40) suggest that C3 activation products
are required for survival after infusion of lipopolysac-
charide (LPS). In contrast, the absence of C5 (C5/
mutant mice) appears to confer some protective effects
in sepsis (15). It has been shown that administration of
C5aRa (F[OPdChaWR]) can antagonize LPS-induced
neutropenia in rats (29, 41). Almost a decade ago, the
hexapeptide MeFKPdChaFR was synthesized by multi-
ple substitutions with unnatural amino acids in the
carboxyl-terminal peptide region of the C5a molecule.
This peptide was shown to exhibit limited antagonistic
effects on C5a-exposed human neutrophils (42, 43).
Increasing the aromaticity of the fifth residue of the
hexapeptide led to an increased C5aR antagonism,
which was reported to be the first full C5aR antagonist
(44). In an attempt to increase the stability and im-
prove target selectivity of the molecule, replacement of
lysine by ornithine and cyclization of the molecule was
carried out, resulting in F[OpdChaWR] (28). This
small C5aRa molecule antagonized the binding of
human C5a to human and rat neutrophils (28, 34). In
the present study, the same C5aRa demonstrated com-
petitive binding for recombinant mouse C5a to mouse
neutrophils (Fig. 2). The incomplete albeit significant
antagonism in binding and the Kd value for C5aRa,
which are dependent on the species from which the
neutrophils are isolated (human, rat or mouse), might
be explained by structural diversity between C5aR of
different species, as shown by 
70% nonhomogeneity
of the extracellular domains of human and mouse
C5aR (45). To determine whether C5aRa antagonizes
the acute inflammatory response, mice were subjected
to immune complex-induced lung injury. The severity
of lung injury as assessed by the pulmonary permeabil-
ity index (Fig. 5) was substantially reduced in the
presence of C5aRa. C5aRa was given intratracheally
based on previous observations that the immune com-
plex-induced lung injury appears to be triggered
mainly by locally generated C5a together with cyto-
kines/chemokines within the lung (36, 46). In rats,
intratracheal instillation of anti-C5a antibodies (which
neutralize C5a) led to similar results in a similar model
of lung injury (36). Supporting these findings and
using the same model of lung injury, C5/ mice have
been reported to exhibit a less severe inflammatory
response than their C5 sufficient littermates (35). To
evaluate the effects of C5aRa on systemic inflammatory
responses, the presence of C5aRa inhibited comple-
ment-induced neutropenia and LPS-induced mortality
in rats (34, 41). Administration of a single dose of
C5aRa (at a weight-related concentration effective in
other species) (34, 41) immediately after induction of
CLP in mice resulted in great improvement of long-
term survival, indicating protective effects of C5aRa
during sepsis (Fig. 6). In rats with CLP, in vivo inter-
ception of C5a with polyclonal antibody to a peptide
from the midregion of C5a reduced lethality (3, 19),
indicating overall protective effects by blockade of the
interaction between C5a and C5aRa. Companion ex-
periments cannot be done in mice because of the lack
of blocking antibodies to mouse C5a.
During CLP-induced sepsis, excessive production of
C5a can lead to a global neutrophil dysfunction as
defined by loss of C5a binding on C5aR (4, 8, 9),
alteration of the chemotactic responsiveness (4, 8, 9), a
defective oxidative burst (3, 10, 19), and impaired
bacterial killing (3, 13). In an attempt to simulate in
vitro pathophysiological conditions present during sep-
sis with reported plasma levels of C5a of 100 ng/mL
serum (8), mouse neutrophils were exposed to increas-
ing amounts of mouse C5a. As expected, a typical
chemotactic response curve of mouse neutrophils to
mouse C5a was observed, but in the copresence of
C5aRa an almost complete dose-dependent inhibition
of the chemotactic response was seen (Fig. 2). With its
capacity for bacterial killing, the neutrophil is known to
be a cornerstone of innate immunity, but neutrophils
also have an implicit capacity for host tissue destruction
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(12) that may contribute to sepsis-induced organ dys-
function/failure. Therefore, it is possible that C5aRa
blockade of C5a may diminish excessive recruitment of
neutrophils and the attendant release of toxic reactive
oxygen species, proteinases, defensins, etc. (12), lead-
ing to protection of tissues and organs. After recruit-
ment and hyperactivation (hyperresponsive phase of
sepsis), neutrophils have been reported to progress to a
hyporesponsive phase (10, 47) with loss of multiple
functions including the respiratory burst (3, 4, 19) and
associated bacterial killing (3). Therefore, we exposed
neutrophils to amounts of C5a appearing during sepsis
(8) in the presence or absence of C5aRa. Preexposure
of 10 nM mC5a led to a loss of respiratory burst in
PMA-stimulated neutrophils (ref 19 and Fig. 3). How-
ever, in the presence of C5aRa, the respiratory burst of
neutrophils (generation of O2
• and H2O2) was pre-
served in proportion to the concentration of C5aRa
(Fig. 3), which may explain why C5aRa is protective in
the CLP model of sepsis.
Other molecules with C5aR antagonistic activity have
been described (48–50). Derived from a human C5a
phage display library in which the carboxyl terminus of
C5a was mutated, these compounds have revealed some
C5a antagonistic effects and have been shown to induce
some protection in different animal models of immune
complex injury. These compounds have also decreased
tissue injury in a model of ischemia and reperfusion
(51). By modification of the carboxyl terminus of C5a,
others found a monomer (C5aRam) and its dimer
(C5aRad) to exhibit potent C5aR antagonistic activity
(52). The latter antagonist reduced infarct size and
attenuated the inflammatory response in a porcine
model of cardiac ischemia/reperfusion injury (53).
Furthermore, a ribosomal protein (S19) has recently
been reported to exhibit (after activation by coagula-
tion factor XIIIa) molecular mimicry for C5a, inhibit-
ing C5a-induced chemotactic responses of leukocytes
(54). Most of these molecules with C5aR antagonistic
activity are large and complex molecules with incon-
stant structures or feature linear peptides that would
likely be rapidly metabolized, have large antigenic
surfaces, and demonstrate unfavorable metabolic pro-
files (41). Although the small acyclic peptide MeFKPd-
ChaFR has been described to be relatively resistant to
protease attack in vitro (41), additional cyclization of
the molecule was performed to achieve increased resis-
tance against proteolytic cleavage and to restrict its
structural freedom (41). In vivo clearance of C5aRa in
mice has not been reported. In the present study, we
labeled the C5aRa with 125I without compromising the
molecule’s biological function as determined by che-
motaxis assays (Fig. 4). Clearance studies were done to
determine blood clearance of C5aRa over time. After
administration of 125I-C5aRa, an initial rapid distribu-
tion phase (over the first 3 h) was found, most likely
due to vascular equilibration (19) and binding to
circulating neutrophils, followed by a slower phase of
clearance with a prolonged half-life of C5aRa. The
relatively slow clearance of C5aRa (at 12 h and 20–25%
of the initially applied dose after 12 h) was unexpected.
Similar results with protective effects of anti-C5a anti-
bodies when administered within the first 12 h after
onset of sepsis have been published recently in rats
(19). The present data suggest that interventions de-
signed to antagonize development of defects of innate
immunity during sepsis in rodents caused by production
of C5a may have application to humans with sepsis.
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